Glaukos Corp
GKOS86.360USD
+0.200+0.23%
Market hours （ET）Quotes delayed by 15 min
4.94BMarket Cap
LossP/E TTM
More Details of Glaukos Corp Company
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Company Info
Ticker SymbolGKOS
Company nameGlaukos Corp
IPO dateJun 25, 2015
CEOMr. Thomas William Burns
Number of employees995
Security typeOrdinary Share
Fiscal year-endJun 25
Address1 Glaukos Way
CityALISO VIEJO
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code92656
Phone19493679600
Websitehttps://www.glaukos.com
Ticker SymbolGKOS
IPO dateJun 25, 2015
CEOMr. Thomas William Burns
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.50M
-0.34%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
38.02K
-2.55%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.50M
-0.34%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
69.52K
+56.16%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
56.36K
+3.89%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
49.23K
+4.47%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
38.02K
-2.55%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
36.18K
+6.19%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Glaucoma
88.14M
82.63%
Corneal Health
18.53M
17.37%
By RegionUSD
Name
Revenue
Proportion
United States
75.07M
70.38%
International
31.59M
29.62%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Glaucoma
88.14M
82.63%
Corneal Health
18.53M
17.37%
Shareholding Stats
Updated: Sun, Aug 3
Updated: Sun, Aug 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.40%
Fidelity Management & Research Company LLC
9.73%
Wellington Management Company, LLP
4.00%
State Street Global Advisors (US)
3.47%
Other
59.06%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.40%
Fidelity Management & Research Company LLC
9.73%
Wellington Management Company, LLP
4.00%
State Street Global Advisors (US)
3.47%
Other
59.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.97%
Investment Advisor/Hedge Fund
34.40%
Hedge Fund
8.12%
Individual Investor
3.33%
Research Firm
1.86%
Pension Fund
1.85%
Sovereign Wealth Fund
1.10%
Bank and Trust
1.05%
Venture Capital
0.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
634
60.63M
105.91%
-341.50K
2025Q1
643
60.20M
105.40%
-1.30M
2024Q4
610
59.75M
105.65%
+533.86K
2024Q3
567
57.47M
104.31%
-894.95K
2024Q2
545
56.86M
103.79%
-713.22K
2024Q1
509
54.47M
110.12%
-1.91M
2023Q4
480
53.71M
109.34%
-1.79M
2023Q3
475
52.90M
108.58%
-1.85M
2023Q2
486
51.69M
106.83%
-2.99M
2023Q1
490
50.54M
105.57%
-3.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.64M
13.38%
-218.59K
-2.78%
Mar 31, 2025
The Vanguard Group, Inc.
5.95M
10.42%
-9.86K
-0.17%
Mar 31, 2025
Fidelity Management & Research Company LLC
5.57M
9.74%
+417.67K
+8.11%
Mar 31, 2025
Wellington Management Company, LLP
2.29M
4.01%
+131.25K
+6.08%
Mar 31, 2025
State Street Global Advisors (US)
1.98M
3.47%
-79.01K
-3.83%
Mar 31, 2025
Burns (Thomas William)
1.50M
2.62%
-5.16K
-0.34%
May 27, 2025
AllianceBernstein L.P.
1.28M
2.24%
+461.39K
+56.53%
Mar 31, 2025
PRIMECAP Management Company
1.22M
2.13%
+4.15K
+0.34%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.22M
2.13%
+17.85K
+1.49%
Mar 31, 2025
Brown Capital Management, LLC
1.19M
2.09%
-155.27K
-11.52%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco S&P SmallCap Health Care ETF
4.22%
Harbor Health Care ETF
2.42%
SPDR S&P Health Care Equipment ETF
1.9%
Invesco S&P SmallCap Momentum ETF
1.66%
ROBO Global Healthcare Technology & Innovation ETF
1.59%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.86%
SPDR S&P 600 Small Cap Growth ETF
0.86%
iShares S&P Small-Cap 600 Growth ETF
0.81%
iShares U.S. Medical Devices ETF
0.67%
SPDR S&P SmallCap 600 ESG ETF
0.62%
View more
Invesco S&P SmallCap Health Care ETF
Proportion4.22%
Harbor Health Care ETF
Proportion2.42%
SPDR S&P Health Care Equipment ETF
Proportion1.9%
Invesco S&P SmallCap Momentum ETF
Proportion1.66%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.59%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.86%
SPDR S&P 600 Small Cap Growth ETF
Proportion0.86%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.81%
iShares U.S. Medical Devices ETF
Proportion0.67%
SPDR S&P SmallCap 600 ESG ETF
Proportion0.62%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
